Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

We aimed to evaluate the cross-sectional association of VitD compounds with glucose homeostasis measurements in pregnant women with overweight/obesity participating in the Vitamin D And Lifestyle Intervention for Gestational Diabetes Mellitus Prevention study.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Secondary analysis.

Secondary analysis

Analyses existing study data; this paper is not automatically another independent trial.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The Weak Relationship between Vitamin D Compounds and Glucose Homeostasis Measures in Pregnant Women with Obesity: An Exploratory Sub-Analysis of the DALI Study

Source: Article title.

A total of 984 women were recruited to participate in the DALI trials [,,].

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The Weak Relationship between Vitamin D Compounds and Glucose Homeostasis Measures in Pregnant Women with Obesity: An Exploratory Sub-Analysis of the DALI Study

Secondary analysis · Nutrients · 2022

Original publication title

The Weak Relationship between Vitamin D Compounds and Glucose Homeostasis Measures in Pregnant Women with Obesity: An Exploratory Sub-Analysis of the DALI Study

Lilian Cristina Mendoza; Jürgen Harreiter; Gernot Desoye; David Simmons; Juan M. Adelantado; Alexandra Kautzky-Willer; Agnieszka Zawiejska; Ewa Wender-Ozegowska; Annunziata Lapolla; Maria G. Dalfra; Alessandra Bertolotto; Roland Devlieger; Fidelma Dunne; Elisabeth R. Mathiesen; Peter Damm; Lisse Lotte Andersen; Dorte Moller Jensen; David Hill; Mireille Nicoline Maria van Poppel; Rosa Corcoy

© 2022 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Studies on the relationship between vitamin D (VitD) and glucose homeostasis usually consider either total VitD or 25OHD3 but not 25OHD2 and epimers. We aimed to evaluate the cross-sectional association of VitD compounds with glucose homeostasis measurements in pregnant women with overweight/obesity participating in the Vitamin D And Lifestyle Intervention for Gestational Diabetes Mellitus Prevention study. Methods: The analysis included 912 women. Inclusion criteria: <20 weeks gestation, body mass index ≥29 kg/m2 and information on exposure and outcome variables at baseline.

Measurements: A 75 g OGTT at <20, 24 to 28 and 35 to 37 weeks gestation (except if previous diabetes diagnosis). Exposure variables: 25OHD2, 25OHD3 and C3-epimer. Outcome variables: fasting and post-challenge insulin sensitivity and secretion indices, corresponding disposition indices (DI), plasma glucose at fasting and 1 and 2 h, hyperglycemia in pregnancy (HiP). Statistics: Multivariate regression analyses with adjustment. Results: Baseline VitD sufficiency was 66.3%. Overall, VitD compounds did not show strong associations with any glucose homeostasis measures. 25OHD3 showed direct significant associations with: FPG at <20 and 24 to 28 weeks (standardized β coefficient (β) 0.124, p = 0.030 and 0.111, p = 0.026 respectively), 2 h plasma glucose at 24 to 28 weeks (β 0.120, p = 0.018), and insulin sensitivity (1/HOMA-IR, β 0.127, p = 0.027) at 35 to 37 weeks; it showed an inverse association with fasting DI (QUCKI*HOMA-β) at <20 and 24 to 28 weeks (β −0.124, p = 0.045 and β −0.148, p = 0.004 respectively). 25OHD2 showed direct associations with post-challenge insulin sensitivity (Matsuda, β 0.149, p = 0.048) at 24 to 28 weeks) and post-challenge DI (Matsuda*Stumvoll phase 1) at 24 to 28 and 35 to 37 weeks (β 0.168, p = 0.030, β 0.239, p = 0.006).

No significant association with C3-epimer was observed at any time period. Conclusions: In these women with average baseline VitD in sufficiency range, VitD compounds did not show clear beneficial associations with glucose homeostasis measures.

Authors’ abstract

Studies on the relationship between vitamin D (VitD) and glucose homeostasis usually consider either total VitD or 25OHD3 but not 25OHD2 and epimers. We aimed to evaluate the cross-sectional association of VitD compounds with glucose homeostasis measurements in pregnant women with overweight/obesity participating in the Vitamin D And Lifestyle Intervention for Gestational Diabetes Mellitus Prevention study. Methods: The analysis included 912 women. Inclusion criteria: <20 weeks gestation, body mass index ≥29 kg/m2 and information on exposure and outcome variables at baseline.

Measurements: A 75 g OGTT at <20, 24 to 28 and 35 to 37 weeks gestation (except if previous diabetes diagnosis). Exposure variables: 25OHD2, 25OHD3 and C3-epimer. Outcome variables: fasting and post-challenge insulin sensitivity and secretion indices, corresponding disposition indices (DI), plasma glucose at fasting and 1 and 2 h, hyperglycemia in pregnancy (HiP). Statistics: Multivariate regression analyses with adjustment. Results: Baseline VitD sufficiency was 66.3%. Overall, VitD compounds did not show strong associations with any glucose homeostasis measures. 25OHD3 showed direct significant associations with: FPG at <20 and 24 to 28 weeks (standardized β coefficient (β) 0.124, p = 0.030 and 0.111, p = 0.026 respectively), 2 h plasma glucose at 24 to 28 weeks (β 0.120, p = 0.018), and insulin sensitivity (1/HOMA-IR, β 0.127, p = 0.027) at 35 to 37 weeks; it showed an inverse association with fasting DI (QUCKI*HOMA-β) at <20 and 24 to 28 weeks (β −0.124, p = 0.045 and β −0.148, p = 0.004 respectively). 25OHD2 showed direct associations with post-challenge insulin sensitivity (Matsuda, β 0.149, p = 0.048) at 24 to 28 weeks) and post-challenge DI (Matsuda*Stumvoll phase 1) at 24 to 28 and 35 to 37 weeks (β 0.168, p = 0.030, β 0.239, p = 0.006).

No significant association with C3-epimer was observed at any time period. Conclusions: In these women with average baseline VitD in sufficiency range, VitD compounds did not show clear beneficial associations with glucose homeostasis measures.

Publication and source details

Original title: The Weak Relationship between Vitamin D Compounds and Glucose Homeostasis Measures in Pregnant Women with Obesity: An Exploratory Sub-Analysis of the DALI Study

Lilian Cristina Mendoza; Jürgen Harreiter; Gernot Desoye; David Simmons; Juan M. Adelantado; Alexandra Kautzky-Willer; Agnieszka Zawiejska; Ewa Wender-Ozegowska; Annunziata Lapolla; Maria G. Dalfra; Alessandra Bertolotto; Roland Devlieger; Fidelma Dunne; Elisabeth R. Mathiesen; Peter Damm; Lisse Lotte Andersen; Dorte Moller Jensen; David Hill; Mireille Nicoline Maria van Poppel; Rosa Corcoy

Nutrients · 2022

* Correspondence: rcorcoy@santpau.cat; Tel.: +34-93-556-56-61© 2022 by the authors.2022https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).European Community’s 7th Framework Programme242187Netherlands Organization for Health Research and Development (ZonMw)200310013Polish Ministry of Science2203/7. PR/2011/2Odense University Free Research FundNIHR Clinical Research Network: EasternCAIBER 1527-B-226DALI has received funding from the European Community’s 7th Framework Programme (FP7/2007 to 2013) under grant agreement no. 242187. In the Netherlands, additional funding was provided by the Netherlands Organization for Health Research and Development (ZonMw) (grant no. 200310013). In Poland, additional funding was obtained from Polish Ministry of Science (grant no. 2203/7. PR/2011/2). In Denmark, additional funding was provided by the Odense University Free Research Fund. In the United Kingdom, the local DALI team was supported by NIHR Clinical Research Network: Eastern. In Spain, additional funding was provided by CAIBER 1527-B-226. The funders had no role in any aspect of the study beyond funding. This sub-study also received funding from the Spanish Diabetes Society (SED) XI Grant for clinical research projects in diabetes lead by young investigators to LM in 2020.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T09:12:13.726719+00:00

DOI: 10.3390/nu14163256 · PMC9415540